Core Viewpoint - Aimeike, known as the "Maotai of the medical beauty industry," has reported disappointing financial results, with significant declines in both revenue and net profit for Q3 2025, raising concerns about its growth prospects and market confidence [1][4]. Financial Performance - Q3 2025 revenue was 565 million, a year-on-year decline of 21.27%, while net profit was 304 million, down 34.61% [1]. - For the first three quarters of 2025, total revenue was 1.865 billion, a decrease of 21.49%, and net profit was 1.09 billion, down 31.05% [1]. - The company's market capitalization has plummeted to approximately 48.5 billion, a staggering drop of about 131.5 billion from its peak of 180 billion in 2021, representing a cumulative decline of 73% [1]. Product Overview - Aimeike specializes in hyaluronic acid products, with two core offerings: the injection solution "Haitai" and the gel filler "Ruhua Tianzi," both of which previously held market advantages [2]. - The company experienced explosive growth from 2016 to 2024, with revenue increasing from 141 million to 3 billion, a cumulative growth of approximately 2000%, and net profit soaring from 53.38 million to 1.956 billion, an increase of 3564% [3]. Market Challenges - Recent performance has shown a marked slowdown, with Q3 2025 results reflecting a significant decline in both revenue and net profit across all quarters [4]. - The revenue for the injection solution "Haitai" in the first half of 2025 was 744 million, down 23.79%, while "Ruhua Tianzi" generated 493 million, a decrease of 23.99% [5][6]. - Despite maintaining high gross margins above 90%, the decline in revenue and slight drop in gross margin have raised concerns about the company's growth momentum [6]. Competitive Landscape - Aimeike's core products are facing increased competition, particularly with the entry of new players like Huaxi Biological's "Runzhi·Gegge," which has disrupted the previously monopolistic market for "Haitai" [8]. - The market for regenerative injectables is becoming crowded, with competitors like Huadong Pharmaceutical and Changchun Shengboma launching similar products, posing a threat to Aimeike's market share [8][9]. Strategic Moves - In 2025, Aimeike acquired 85% of South Korean company REGEN for 1.9 billion USD to seek new growth avenues, aiming to leverage REGEN's technology and global sales network [10]. - This acquisition has led to a significant increase in goodwill from 278 million at the end of 2024 to 1.65 billion by September 2025, a rise of 493.44% [11]. - However, Aimeike is embroiled in a legal dispute with REGEN's former distributor, which could impact the integration and future profitability of the acquisition [12][13].

Core Viewpoint - Aimeike, known as the "Maotai of the medical beauty industry," has reported disappointing financial results, with significant declines in revenue and net profit, raising concerns about its growth prospects and market confidence [1][2]. Financial Performance - In Q3 2025, Aimeike's revenue was 565 million, a year-on-year decline of 21.27%, and net profit was 304 million, down 34.61% [1]. - For the first three quarters of 2025, total revenue was 1.865 billion, a decrease of 21.49%, and net profit was 1.09 billion, down 31.05% [1]. - The company's market capitalization has dropped to approximately 48.5 billion, a staggering decline of about 73% from its peak of 180 billion in 2021 [1]. Product Performance - Aimeike's core products, "Haitai" and "Ruhua Tianzi," have seen significant revenue declines, with "Haitai" revenue down 23.79% and "Ruhua Tianzi" down 23.99% in the first half of 2025 [3][4]. - Despite maintaining high gross margins above 90%, the revenue drop indicates a weakening market position [6]. Competitive Landscape - The competitive advantage of Aimeike's core products is diminishing, particularly with the entry of new competitors like Huaxi Biological's "Runzhi·Gege," which has disrupted the monopoly of "Haitai" [7]. - The market for "Ruhua Tianzi" is also becoming crowded, with several companies launching similar products, increasing competitive pressure [8][9]. Strategic Moves - In 2025, Aimeike acquired 85% of South Korean company REGEN for $190 million to diversify its product offerings and enhance its international market presence [10]. - This acquisition has led to a significant increase in goodwill from 278 million at the end of 2024 to 1.65 billion by September 2025, a rise of 493.44% [11]. Legal Challenges - Aimeike is currently embroiled in a legal dispute with REGEN's former distributor, which could impact the integration and future profitability of the acquisition [12]. - The dispute centers around a unilateral termination of the exclusive distribution agreement, with potential claims of up to 1.6 billion in damages from the distributor [12]. Conclusion - Aimeike is at a critical juncture, facing declining performance in its flagship products while attempting to pivot through acquisitions. The erosion of its previous competitive advantages and the emergence of legal challenges pose significant risks to its future growth trajectory [11][12].

昌平区作为北京美丽健康产业集聚区，目前已集聚爱美客（300896）等164家优质企业，美丽健康产业 2024年产业收入超过123亿元，年均增长率22%，三年构建一个百亿级产业集群。此次获批标志北京市 化妆品产业创新示范区建设取得新突破，我国在化妆品着色技术领域实现从"跟跑"到"领跑"的历史性跨 越，将进一步扩大北京市美丽经济影响力，助力打造全球美丽健康产业创新之城、消费之城、未来之 城。 新京报讯 据"北京昌平"微信公众号消息，10月30日，昌平区化妆品原料领域迎来重大突破——北京尚 捷优蓝科技有限公司自主研发的"2-（4'-偶氮-苯胺聚氧乙烯醚）-4-甲基苯并噻唑基水性聚氨酯"（商品 名：安色 洛神朱）正式通过国家药品监督管理局（NMPA）审批，成为全国首个获批国产化妆品原料 注册证企业，同时，该原料也成为全球首个获批用于化妆品领域的高分子着色剂。 这是自2021年《化妆品新原料注册备案资料管理规定》实施以来，第二个成功获批的注册类新原料，标 志着我国化妆品着色技术领域实现从"跟跑"到"领跑"的历史性跨越。 ...

Core Viewpoint - The first-mover advantage of Aimeike is gradually diminishing, leading to a significant decline in revenue and net profit in recent quarters, indicating increased competition and changing market dynamics [3][4]. Group 1: Financial Performance - In Q3 2025, Aimeike reported a revenue of 1.865 billion yuan, a year-on-year decrease of 21.49%, and a net profit of 1.093 billion yuan, down 31.05% [3][5]. - The company's two main business segments, represented by "Ruhbai Angel" and "Haitai," which account for over 95% of revenue, have both seen a revenue decline of around 20% in the first half of the year [5][6]. - Aimeike's gross margin remains high at 93.4% for the first three quarters of this year, maintaining above 93% for the past three years [6]. Group 2: Market Challenges - The medical beauty industry is facing challenges such as insufficient consumer confidence and intensified competition, with new entrants diluting Aimeike's market share [3][5]. - Competitors have introduced similar products at significantly lower prices, such as Huaxi Biological's "Runzhi·Gege," which is priced at 30%-50% of "Haitai," directly impacting Aimeike's customer base [5][6]. - The number of approved products in the market has increased, leading to a more competitive landscape for Aimeike's offerings [6]. Group 3: Strategic Initiatives - Aimeike plans to enhance market competitiveness by focusing on core business, diversifying product lines, and improving service levels and brand influence [9][10]. - The company has begun expanding into skincare and cosmetic raw materials, launching the "Haitai Skincare" series and filing for new cosmetic ingredients [10][11]. - Aimeike has also made strategic acquisitions, such as the purchase of REGEN Biotech for nearly 1.4 billion yuan to strengthen its gel injection product line [6][10].

Core Viewpoint - Aimeike (300896.SZ), a leading player in the medical beauty industry, is experiencing a decline in revenue and net profit, indicating a loss of its competitive edge as new entrants flood the market [1][2]. Financial Performance - In Q3 2025, Aimeike reported revenue of 1.865 billion yuan, a year-on-year decrease of 21.49%, and net profit of 1.093 billion yuan, down 31.05% [1][2]. - The company's gross margin remains high at 93.4%, consistent over the past three years [3][7]. - The company's market capitalization has dropped over 70% from its peak of 172.2 billion yuan in 2021 to 48.4 billion yuan as of October 31, 2025 [7]. Business Challenges - Aimeike's two main business lines, represented by "Haitai" and "Ruhua Tianzi," which account for over 95% of its revenue, are facing significant challenges with a revenue decline of around 20% in the first half of 2025 [2][3]. - Increased competition from new products, such as "Runzhi·Gegge" and "Tongyan Needle," has diluted Aimeike's previous market dominance [2][3]. Strategic Responses - Aimeike plans to enhance market competitiveness by focusing on core business, diversifying product lines, and improving service levels [1][6]. - The company has begun expanding into skincare and cosmetic raw materials, launching the "Haitai Skincare" series and filing for new cosmetic ingredients [6][7]. - Aimeike acquired REGEN Biotech for nearly 1.4 billion yuan to strengthen its gel injection product line, although this acquisition has led to disputes over exclusive agency rights [3][4]. Future Outlook - Aimeike aims to transform into a diversified international giant covering both medical and beauty sectors, with ongoing research in biopharmaceuticals and surgical repair [6][7]. - The contribution of its two main business lines to total revenue has decreased from 98.1% in mid-2024 to 95.3% in mid-2025, indicating a gradual shift towards other business areas [7].

Core Insights - The Biotech Index (970038) closed at 2279.35 points, up 0.77%, with a trading volume of 28.709 billion yuan and a turnover rate of 1.85% [1] - Among the index constituents, 41 stocks rose, with Hualan Vaccine leading at a 17.88% increase, while 8 stocks fell, with Deep Technology leading the decline at 6.38% [1] Index Performance - The Biotech Index saw a net inflow of 140 million yuan from institutional investors, while retail investors contributed a net inflow of 210 million yuan, and there was a net outflow of 350 million yuan from speculative funds [1] Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 215.04, and a decrease of 0.76% [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 112.26, and a decrease of 2.55% [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 33.51, and an increase of 1.12% [1] - Other notable constituents include Muyuans (sz002714) and Aimeike (sz300896) with respective weights of 3.66% and 3.44% [1] Capital Flow Details - Detailed capital flow for key stocks includes: - Mindray Medical saw a net inflow of 26.2 million yuan from institutional investors [2] - Muyuans had a net inflow of 203 million yuan from institutional investors [2] - Hualan Vaccine experienced a net inflow of 74.8 million yuan from institutional investors [2]

爱美客技术发展股份有限公司 规范与关联方资金往来管理制度 爱美客技术发展股份有限公司 规范与关联方资金往来管理制度 第一章 总 则 第一条 为了规范爱美客技术发展股份有限公司(以下简称"公司")与公司 关联方的资金往来,避免公司关联方占用公司资金,保护公司、股东和其他利益相 关人的合法权益,建立防范公司关联方占用公司资金的长效机制,根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司治理准则》《深圳证券交易 所创业板股票上市规则》》《上市公司监管指引第 8 号——上市公司资金往来、对 外担保的监管要求》等有关法律、法规和规范性文件及《爱美客技术发展股份有 限公司章程》（以下简称《公司章程》）的规定制定本制度。 第二条 纳入公司合并会计报表范围的子公司与公司关联方之间进行的资金 往来适用本制度。 第三条 本制度所称的关联方与《深圳证券交易所创业板股票上市规则》规 定的关联方具有相同含义。 经营性资金占用,是指公司关联方通过采购、销售等生产经营环节的关联交 易所产生的对公司的资金占用。 爱美客技术发展股份有限公司 规范与关联方资金往来管理制度 非经营性资金占用,是指公司为公司关联方垫付工资、福利、保险 ...

爱美客技术发展股份有限公司 募集资金管理制度 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新能力。 募集资金到位后,公司应及时办理验资手续，聘请符合《证券法》规定的会 计师事务所出具验资报告，并应立即按照招股说明书或可转债募集说明书所承诺 的募集资金使用计划，组织募集资金的使用工作。 第四条 公司董事会应当持续关注募集资金存放、管理和使用情况，有效防 范投资风险，提高募集资金使用效益。 公司的董事、高级管理人员应当勤勉尽责，确保公司募集资金安全，不得操 控公司擅自或变相改变募集资金用途。 第五条 董事会应根据有关法律、行政法规和公司章程的规定，及时披露募 集资金的使用情况。 爱美客技术发展股份有限公司 募集资金管理制度 募集资金限用于公司对外公布的募集资金投向的项目，公司董事会应制定详 第一章 总 则 1 第一条 为规范爱美客技术发展股份有限公司（以下简称公司）募集资金管 理，提高募集资金使用效率，保护股东权益，根据《公司法》《证券法》《深圳证 券交易所创业板股票上市规则》《深圳证 ...

爱美客技术发展股份有限公司 独立董事工作制度 爱美客技术发展股份有限公司 独立董事工作制度 第一章 总 则 第一条 为进一步完善爱美客技术发展股份有限公司（以下简称"公司"） 的法人治理结构，强化对董事会和管理层的约束和监督机制，更好地维护中小股 东的利益，促进公司的规范运作，根据《中华人民共和国公司法》《上市公司独 立董事管理办法》（以下简称"《独立董事管理办法》"）《深圳证券交易所创业 板股票上市规则》（以下简称"《创业板上市规则》"）《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律、行政法规、 规范性文件和《爱美客技术发展股份有限公司章程》（以下简称《公司章程》）等 相关规定，制定本制度。 第二条 独立董事是指不在公司担任除董事之外的其他职务，并与公司及其 主要股东、实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独 立客观判断的关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、深圳证 券交易所业务规则和《公司章程》的规定，认真履行职责，在董事会中发挥参与 决策 ...

爱美客技术发展股份有限公司 防范大股东及关联方资金占用专项制度 爱美客技术发展股份有限公司 防范大股东及关联方资金占用专项制度 第一章 总 则 第一条 为了建立防止控股股东及其关联方占用爱美客技术发展股份有限公 司（以下简称"本公司"或"公司"）资金的长效机制，杜绝控股股东及其关联 方占用资金行为的发生，根据《中华人民共和国公司法》《中华人民共和国证券 法》 《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》 《深圳证券交易所创业板股票上市规则》等法律、法规及规范性文件及《爱美客 技术发展股份有限公司章程》（以下简称《公司章程》）的相关规定，结合公司实 际情况，制定本制度。 第二条 本制度适用于公司及纳入公司合并会计报表范围的子公司与公司控 股股东及其关联方之间的资金往来管理。 第三条 公司董事、高级管理人员对维护公司资金安全负有法定义务。 第四条 占用资金包括经营性占用资金和非经营性占用资金。 经营性占用资金是指控股股东及其关联方通过采购、销售等生产经营环节的 关联交易产生的占用资金。 非经营性占用资金是指为控股股东及其关联方垫付工资、福利、保险、广告 等费用和其他支出，代控股股东及其关 ...